MAP2K3

Across TCGA pan-cancer cohorts, MAP2K3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MAP2K3’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MAP2K3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAP2K3 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

PDAC, HNSC, and CCRCC are the cancer types where MAP2K3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2K3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	+0.402	<.001	8	view →
HNSC	Male	II,III,IV	−0.201	<.001	8	view →
CCRCC	All	All	+0.087	<.001	7	view →
LSCC	Male	All	−0.134	<.001	4	view →
LUAD	All	All	−0.080	.006	2	view →
COAD	Female	IV	+0.207	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MAP2K3–PDAC

Open the PDAC breakdown →